Core Points - Chengdu Jiachi Electronic Technology Co., Ltd. has completed the use of raised funds for the project "Supplementary Working Capital" and has decided to cancel the corresponding special account for these funds [2][4]. Fundraising Overview - The company successfully issued 40.01 million shares of ordinary stock, raising a total of RMB 1,083.47 million, with a net amount of RMB 1,002.76 million after deducting issuance costs of RMB 80.71 million [3]. Fund Management and Usage - The company established a management system for the raised funds to ensure compliance with relevant laws and regulations, including the establishment of special accounts for fund storage and signing of supervisory agreements with banks and sponsors [4]. - The company has adhered to strict approval procedures for the use of raised funds, ensuring transparency and compliance in the management and usage of these funds [4]. Cancellation of Special Account - The special account related to the "Supplementary Working Capital" project has been fully utilized, leading to the decision to cancel the account to reduce management costs and facilitate account management [4].

Core Viewpoint - Zhejiang Dongya Pharmaceutical Co., Ltd. has received a corrective order from the Zhejiang Securities Regulatory Bureau, requiring the company to rectify issues related to the use of raised funds and information disclosure [8][10]. Financial Data - The third-quarter financial report for 2025 has not been audited [3]. - The company reported that the net amount raised from its initial public offering (IPO) was approximately RMB 782.44 million after deducting various fees [37]. Rectification Measures - The company plans to permanently adjust the use of funds from the R&D center construction project to an administrative complex, while maintaining the existing R&D areas [11][44]. - The company has organized training for relevant personnel to enhance compliance awareness and prevent future issues related to fund management [13][14]. Board and Supervisory Meetings - The 11th meeting of the 4th Board of Directors and the 10th meeting of the 4th Supervisory Board were held on October 30, 2025, to discuss and approve the third-quarter report and the adjustment of the R&D center project [19][29]. - Both meetings confirmed that the adjustments to the project would not negatively impact the company's economic benefits or the implementation of the IPO fundraising projects [33][45]. Compliance and Governance - The company emphasizes the importance of improving internal controls and compliance with securities laws following the corrective order [15]. - The company aims to enhance its governance and operational standards to protect the interests of shareholders and investors [15].

Core Viewpoint - The company has announced its third-quarter report for 2025, confirming the authenticity and completeness of the financial information presented, and has made decisions regarding its employee stock ownership plan and the use of surplus funds from a previous bond issuance [8][14][45]. Financial Data - The third-quarter financial report for 2025 has not been audited [3]. - The company reported a surplus of 254.44 million yuan from its 2020 convertible bond issuance, which is approximately 17.07% of the net amount raised [45][46]. Shareholder Information - The company will hold its second extraordinary general meeting of 2025 on November 20, 2025, using a combination of on-site and online voting methods [25][26]. - The meeting will address several key proposals, including the approval of the employee stock ownership plan and the use of surplus funds [19][20]. Employee Stock Ownership Plan - The board has approved the draft of the 2025 employee stock ownership plan, which aims to enhance the alignment of interests between shareholders and key employees [15][17]. - The plan requires approval from the upcoming extraordinary general meeting [16][21]. Use of Surplus Funds - The company plans to permanently supplement its working capital with the surplus funds from the 2020 convertible bond issuance, which will improve the efficiency of fund utilization [45][52]. - The decision to use surplus funds has been reviewed and approved by the board and its audit committee, ensuring compliance with relevant regulations [53].

Group 1 - The company has announced the completion of the 2GWh sodium-ion battery project and plans to permanently supplement its working capital with the remaining raised funds amounting to 23.83 million yuan [10][11][19] - The total investment for the sodium-ion battery project was 682.11 million yuan, with 200 million yuan allocated from the raised funds for equipment purchase and installation [11][12] - The board of directors approved the project completion and fund allocation without requiring shareholder approval, in compliance with relevant regulations [10][22] Group 2 - The company’s subsidiary, Shenzhen Lurun Energy Co., Ltd., is set to engage in a financing lease with related party Donghai Financing Lease Co., Ltd., for 32 million yuan at an internal rate of return (IRR) of 5.1% over 24 months [27][29] - This financing lease is aimed at expanding funding channels and ensuring the normal operation of the company and its projects [29][48] - The transaction has been approved by the board and does not constitute a major asset restructuring as per regulatory definitions [27][28][32] Group 3 - The company will hold a performance briefing on November 21, 2025, to discuss the third-quarter results and address investor inquiries [55][56] - The meeting will be conducted online, allowing investors to submit questions in advance [56][58] - This initiative aims to enhance transparency and communication with investors regarding the company's financial performance [55][57]

Core Viewpoint - The company has announced the completion of certain fundraising projects and the permanent allocation of surplus funds to supplement working capital, along with the cancellation of related fundraising accounts [8][9][12]. Financial Data - The company reported that the total amount raised from the public offering was approximately RMB 547.67 million, with net proceeds after deducting issuance costs amounting to approximately RMB 500.82 million [8]. - The company has stated that the fundraising project "Mineralized Collagen/Polyester Artificial Bone and Collagen Sponge R&D Project" has been completed, and the surplus funds will be used to permanently supplement working capital [9][12]. Fundraising Project Details - The company has decided to conclude the aforementioned fundraising project and will cancel the related fundraising accounts, which will not affect the normal operation of the fundraising project [13]. - The surplus funds amount to approximately RMB 523,800, including interest income, which will be used for daily operational activities [12]. Opinions from Supervisory and Sponsoring Institutions - The supervisory board believes that the decision to conclude certain fundraising projects and allocate surplus funds is beneficial for improving the efficiency of fund usage and reducing financial costs, aligning with the interests of all shareholders [14]. - The sponsoring institution, Huatai United Securities, has confirmed that the decision-making process was properly followed and supports the allocation of surplus funds as a prudent decision that optimizes resource allocation [15].

Core Viewpoint - The company, Zhejiang Zhuojin Environmental Technology Co., Ltd., has announced the use of its own funds to pay personnel costs for fundraising projects and will replace these amounts with raised funds, ensuring compliance with regulations and maintaining operational efficiency [7][9][12]. Financial Data - The company reported that the total amount raised from its initial public offering was RMB 251.099 million, with a net amount of RMB 200.792 million after deducting issuance costs [7]. - The company has implemented a special account management system for the raised funds, ensuring that all expenditures are made from this account [7]. Fund Usage - The company has decided to conclude the "Enterprise Technology R&D Center Project" and redirect surplus funds from the "Branch Construction Project" to the "Industrial Three Wastes Comprehensive Treatment and Resource Utilization R&D Project" [8]. - The company plans to use its own funds to cover personnel costs during the implementation of fundraising projects, which will later be replaced with raised funds to comply with banking regulations [9][10]. Approval Process - The decision to use self-owned funds for personnel costs and subsequently replace them with raised funds was approved by the company's board and audit committee [11][12]. - The sponsor institution has reviewed and agreed that this arrangement does not affect the normal implementation of fundraising projects and complies with relevant regulations [12][13].

Core Viewpoint - The company, Zhejiang Zhongxin Environmental Technology Group Co., Ltd., is undertaking significant corporate actions including the absorption merger of its wholly-owned subsidiaries and the management of idle funds to enhance operational efficiency and shareholder returns [9][15][70]. Financial Data - The company reported that its third-quarter financial statements are unaudited, and it has provided key financial data and indicators for the period [3][7]. - The company has adjusted previous financial figures, reducing management expenses by 2,300,321.67 yuan and increasing sales and R&D expenses [6]. Shareholder Information - The company has confirmed that there are no changes in the major shareholders or their shareholding status due to the proposed actions [5][11]. Cash Management - The company plans to use up to 30 million yuan of temporarily idle raised funds for cash management, focusing on low-risk, high-liquidity financial products [16][21]. - The cash management will be valid for 12 months and can be rolled over within this period [21][31]. Merger and Restructuring - The company has approved the absorption merger of its wholly-owned subsidiaries, aiming to optimize management structure and reduce costs [9][10]. - The merger does not constitute a related party transaction or a significant asset restructuring as per regulatory definitions [9]. Risk Management - The company has established risk control measures for its cash management and foreign exchange derivative trading, ensuring compliance with relevant regulations and safeguarding shareholder interests [28][63]. Upcoming Shareholder Meeting - The company has scheduled a second extraordinary general meeting for shareholders on November 18, 2025, to discuss various proposals including the foreign exchange derivative trading business [88].

Core Viewpoint - The company has effectively managed its idle raised funds by temporarily supplementing working capital and has returned the full amount to the designated account within the stipulated time frame, demonstrating compliance with regulatory requirements and internal financial management policies [1][2]. Group 1: Fund Management - On October 29, 2024, the company announced the return of 290 million yuan of idle raised funds to the designated account, which was previously used to temporarily supplement working capital [1]. - The board approved the use of up to 290 million yuan of idle raised funds for working capital, with a usage period not exceeding 12 months from the date of approval [1]. - The company has returned the full amount of 290 million yuan to the designated account by October 28, 2025, without exceeding the usage period and without any overdue situations [1]. Group 2: Financial Efficiency - The return of funds reflects the company's commitment to the regulated management of raised funds, enhancing fund utilization efficiency while adhering to usage agreements [2]. - The rational use of idle raised funds to supplement working capital is seen as beneficial for optimizing cash flow structure and reducing financial costs [2]. - Timely and full repayment of the funds further emphasizes the company's prudent attitude towards financial management [2].

Core Points - Jiangsu Hongwei Technology Co., Ltd. has fully repaid the idle raised funds of 6 million yuan used for temporary liquidity support, complying with regulatory requirements [1][2] Group 1: Fund Usage and Repayment - The company held a board meeting on October 30, 2024, approving the use of 6 million yuan of idle raised funds for liquidity support related to its main business, with a usage period of 12 months [2] - The funds were sourced from the company's initial public offering (IPO) in 2021, with the initial receipt date being August 27, 2021 [2] - The full repayment of the 6 million yuan was completed on October 27, 2025, with no overdue situation reported [2] Group 2: Management and Compliance - The proper use and timely repayment of the idle raised funds reflect the company's prudent attitude towards fund management, enhancing fund efficiency while ensuring safety [2] - The company commits to continue adhering to the Shanghai Stock Exchange's regulations and its own fund management policies to ensure that the fund usage aligns with the intended purposes [2]

Core Points - The company held its 19th meeting of the 6th Board of Directors on October 27, 2025, where several resolutions were passed regarding the management and utilization of raised funds [2][3][5]. Group 1: Fund Management and Utilization - The company approved the establishment of a special account for raised funds and signed a tripartite/four-party supervision agreement for fund storage [3]. - The company decided to adjust the actual investment amount of raised funds for specific projects in 2023 [4]. - The company will use part of the idle raised funds for cash management, with a limit of up to 200 million yuan [38]. Group 2: Fund Allocation to Subsidiaries - The company approved the use of raised funds to increase capital or provide loans to its wholly-owned subsidiary, Jiangxi Brother Pharmaceutical Co., Ltd., for project implementation [10][11]. - The total amount allocated for this purpose is 42,824.88 million yuan, which includes net interest income and financial gains [11][12]. Group 3: Fund Replacement and Reimbursement - The company will replace pre-invested self-raised funds and paid issuance expenses with raised funds, totaling 222,647,327.66 yuan [20][21]. - The company will ensure that the replacement of funds does not affect the normal implementation of the investment projects [22][23]. Group 4: Project Timeline and Adjustments - The company announced a delay in the project timeline for the "Annual Production of 600 Tons of Iodinated Contrast Agent Construction Project" to September 2026 [56][57]. - This delay is due to the later-than-expected arrival of raised funds, which has slowed the investment progress [57].